XML 52 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1
The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)
 6 Months Ended
Jun. 10, 2024
EUR (€)
share
€ / shares
Jun. 30, 2024
EUR (€)
€ / shares
Jun. 30, 2023
EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share 106,844    
Exercise and subscription of equity instruments | €   € 93,000 € 348,000
Ordinary Shares      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share 38,100    
Par value per share (in EUR per share) | € / shares   € 0.05  
Free Shares      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Share issued, price per share (in EUR per share) | € / shares € 2.45    
Exercise Of Share Warrants | Ordinary Shares      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share 68,744    
Definitive Acquisition Of Free Shares      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Par value per share (in EUR per share) | € / shares € 0.05    
Ordinary Shares      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Par value per share (in EUR per share) | € / shares € 0.05    
Issued capital free of subscription      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share 68,744    
Share premium      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Exercise and subscription of equity instruments | €   € 88,003 333,000
Share premium | Free Shares      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Exercise and subscription of equity instruments | € € 91,440    
Agreement with Sanofi, 2016      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Milestone payment received | €   € 4,000,000 € 2,000,000